Previous 10 | Next 10 |
BELTSVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will parti...
BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will par...
The following slide deck was published by NextCure, Inc. in conjunction with this event. For further details see: NextCure (NXTC) Presents At 20th Annual Needham Healthcare Conference - Slideshow
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and ...
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pre...
Truist Securities analyst Asthika Goonewardene has upgraded NextCure ([[NXTC]] +1.8%) to buy from hold on the remarks made by the management at the recently-concluded R&D Update Event.The price target at $19.00 per share indicates ~66.8% upside to the previous close.Noting that R&D up...
XTL Biopharmaceuticals (XTLB) +93%.Second Sight Medical Products, Inc. (EYES) +50%.Fulgent Genetics, Inc. (FLGT) +32% on Q4 results.CLPS Incorporation (CLPS) +29% on FQ2 results.Sify Technologies Limited (SIFY) +26% on report of Blackstone buying minority stake.Waitr Holdings (...
NextCure (NXTC): FY GAAP EPS of -$1.33 beats by $0.01.Revenue of $22.38M (+252.4% Y/Y) in-line.Press Release For further details see: NextCure EPS beats by $0.01, revenue in-line
BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter an...
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will hos...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...